Biotech entity
Every one of those 3 sits in a single category, fda-approval. Of the tracked stories, 3 of 3 also mention FDA, the most common co-covered peer. That works out to roughly 2.6 stories per week across an 8-day span. At 5.7, the average consequence score sits below the same-window beat average of 5.9.
Last mentioned: Aug 3, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 3 sits in a single category, fda-approval. Of the tracked stories, 3 of 3 also mention FDA, the most common co-covered peer. That works out to roughly 2.6 stories per week across an 8-day span. At 5.7, the average consequence score sits below the same-window beat average of 5.9. Source depth averages 2.3 original sources per story, versus 2.4 across the same-window beat baseline. We currently track 3 Biotech stories that mention BPC-157, published between July 27, 2026 and August 3, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 62 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering BPC-157. Shared-story counts are live from our verified record — not editorial picks.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
FDA Advisory Panel Hearing
Marathon hearing votes 6-1 to back compounding of six peptide therapies, including BPC-157, TB-500, and MOTS-c, despite FDA scientists' concerns.
Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Source: wknofm.org · wmuk.org
An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
A divided FDA panel backed three unapproved peptides for pharmacy compounding despite agency warnings of insufficient safety data. The vote raises concerns about political influence and the erosion of evidence-based standards in biopharmaceutical regulation.
Source: nbcdfw.com · nbcnewyork.com
BPC-157 is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
